COMMUNIQUÉS West-GlobeNewswire

Orvida Pharma (formerly Kamari Pharma) Announces Favorable Phase 1a Safety Data for KM-023, a Potential First-in-Disease Oral TRPV3 Inhibitor, and Initiation of Phase 1b Study in Patients with Olmsted Syndrome
15/04/2026
First Olmsted syndrome patient dosed in global Phase 1b study Company now operating under its new name, Orvida Pharma NESS ZIONA, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Orvida Pharma (formerly Kamari Pharma), a [...]
BioCryst to Report First Quarter 2026 Financial Results on May 6
15/04/2026
RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on Wednesday, May 6, [...]
Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership
15/04/2026
Tilray Advances UK Healthcare Platform with Lyphe Acquisition, Positions BrewDog for Strong Growth, and Prepares for U.S. Rescheduling and Medical Cannabis Opportunity NEW YORK and LEAMINGTON, Ontario, April 15, 2026 ( [...]
Stereotaxis Announces Definitive Agreement to Acquire Robocath
15/04/2026
ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has [...]
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
15/04/2026
For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground™ Schizophrenia Community is a centralized destination that delivers peer- [...]
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
15/04/2026
GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve [...]
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
15/04/2026
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- TG [...]
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
15/04/2026
MELBOURNE, Australia and SAN FRANCISCO, April 15, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
15/04/2026
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or [...]
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
15/04/2026
WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”), a clinical-stage precision oncology company, today announced that Dr. [...]
neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada
15/04/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Health Canada has approved neffy ® 2 mg for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal [...]
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
15/04/2026
Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). Phase Ib/II study will [...]
Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS
15/04/2026
LONDON, April 15, 2026 (GLOBE NEWSWIRE) -- A new white paper entitled “Inside the Science: A Major Step Forward for Knee Osteoarthritis” has been released which heralds the dawn of a new era of treatments for knee [...]
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
15/04/2026
Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve as first President [...]
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
15/04/2026
Updated Safety, Efficacy, and Clinical Data Supports Teverelix as Potentially the First Long-Acting Injectable GnRH Antagonist Across Multiple Indications in Women’s Health PHILADELPHIA, April 15, 2026 (GLOBE NEWSWIRE [...]
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
15/04/2026
Health economics and reimbursement expert brings over two decades of experience in payer strategy, value-based pricing, and health policy supporting CNSide adoption and long-term commercialization strategy for REYOBIQ™ [...]
Aerska Strengthens Leadership and Board with Key Appointments to Advance Systemically Delivered RNA Medicines for the Brain
15/04/2026
Stuart Milstein appointed Chief Platform Officer, bringing decades of experience in oligonucleotide drug development to underpin Aerska’s platform R&D Lisa Taylor Ash joins Board of Directors, strengthening [...]
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
15/04/2026
TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime, is the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years TONMYA commercially launched in the U.S. in [...]
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
15/04/2026
neffy offers a new delivery method for epinephrine in Canada for adults and children ( > 30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market neffy in Canada, expects [...]

Pages